156 results
424B5
AMPE
Ampio Pharmaceuticals Inc
25 Jan 24
Prospectus supplement for primary offering
4:18pm
to file our full IND submission and initiate a Phase 1/2 clinical study by the first and second quarter of 2025, respectively, with safety
424B5
AMPE
Ampio Pharmaceuticals Inc
24 Jan 24
Prospectus supplement for primary offering
5:16pm
by the first and second quarter of 2025, respectively, with safety and efficacy data from the clinical study available in the third quarter of 2026
8-K
EX-99.1
uv9t7kosmbhgpdnhx
2 Nov 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
hcixq
6 Oct 23
Regulation FD Disclosure
2:56pm
DEFA14A
wpjos hwzg9z2ofwf7qv
4 Aug 22
Additional proxy soliciting materials
8:52am
8-K
EX-99.1
a0vwcmh71dvcj
3 Aug 22
Ampio Pharmaceuticals’ Chairman of the Board Kevin Buchi and CEO Mike Martino Issues Letter to Stockholders
8:36am
8-K
hyynlpbz cu5el8n
3 Aug 22
Ampio Pharmaceuticals’ Chairman of the Board Kevin Buchi and CEO Mike Martino Issues Letter to Stockholders
8:36am
8-K
EX-99.1
uo1h2z9 nho2s1
2 Jun 22
Ampio Pharmaceuticals’ CEO Mike Martino Issues Letter to Stockholders
4:35pm